Abstract 17169: The Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial

E. Bohula,R. Giugliano,C. Ruff,J. Kuder,S. Murphy,E. Antman,E. Braunwald

Published 2015 in Circulation

ABSTRACT

No abstract is available for this paper.

PUBLICATION RECORD

Publication year
2015
Venue
Circulation
Publication date
2015-11-10
Fields of study
Medicine
Identifiers
No identifiers available.
External record
Open on Semantic Scholar
Source metadata
Semantic Scholar

CITATION MAP

EXTRACTION MAP

CLAIMS

No claims are published for this paper.

CONCEPTS

No concepts are published for this paper.

REFERENCES

No references are available for this paper.

CITED BY

Efficacy and safety of oral anticoagulants in the treatment of chronic kidney disease with atrial fibrillation or venous thromboembolism: a systematic review and meta-analysis
2025cites this paper
Optimizing care for chronic kidney disease: Considerations from A to Z
2025cites this paper
Brazilian Atrial Fibrillation Guidelines - 2025.
2025cites this paper
Literature-based case analysis of serious adverse drug events associated with edoxaban
2025cites this paper
Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III
2025influential citation
Comparison of outcomes of direct oral anticoagulants versus vitamin K antagonists for atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis
2025cites this paper
Edoxaban pharmacokinetics during in vitro continuous renal replacement therapy
2024cites this paper
Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial.
2024cites this paper
Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry
2024cites this paper
Effect of impaired kidney function on outcomes and treatment effects of oral anticoagulant regimes in patients with atrial fibrillation in a real-world registry
2024cites this paper
Cardiovascular and non‐renal complications of chronic kidney disease: Managing risk
2024influential citation
Comparative effectiveness of factor Xa non-vitamin K antagonist oral anticoagulants versus phenprocoumon in patients with non-valvular atrial fibrillation.
2024cites this paper
Fracture in Association with Anticoagulant Therapy in Patients with CKD and Atrial Fibrillation
2024cites this paper
The impact of renal function on clinical outcomes of patients with cancer-associated isolated distal deep vein thrombosis: Insights from the ONCO DVT study.
2024cites this paper
Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial Fibrillation
2024cites this paper
Antithrombotic Therapy for Patients Undergoing Cardiac Electrophysiological and Interventional Procedures: JACC State-of-the-Art Review.
2024cites this paper
Safety and efficacy of direct oral anticoagulants in chronic kidney disease: a meta-analysis
2024cites this paper
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
2024cites this paper
Oral Anticoagulation Use in Individuals With Atrial Fibrillation and Chronic Kidney Disease: A Review.
2024cites this paper
Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?
2024cites this paper
Prescription of DOACs in Patients with Atrial Fibrillation at Different Stages of Renal Insufficiency
2023influential citation
Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region
2023cites this paper
Edoxaban Anticoagulation in Atrial Fibrillation: Real-World Data and Evidence.
2023cites this paper
Renal Function and Clinical Outcomes Among Elderly Patients With Nonvalvular Atrial Fibrillation From ANAFIE
2023cites this paper
Anticoagulation in Elderly Patients With Atrial Fibrillation and Renal Dysfunction
2023cites this paper
Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation on chronic hemodialysis: a meta-analysis of randomized controlled trials
2023cites this paper
Pharmacokinetic relevance of glomerular hyperfiltration for drug dosing
2023influential citation
Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop
2023cites this paper
Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis
2023influential citation
Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF
2023cites this paper
Management of edoxaban therapy and clinical outcomes in patients undergoing major or nonmajor surgery: a subanalysis of the EMIT-AF/VTE study
2023cites this paper
Prescriptive behavior of non-vitamin K oral anticoagulants in patients affected by atrial fibrillation in general practice.
2023cites this paper
Use of direct oral anticoagulants for venous thromboembolism treatment at extremes of body weight, renal and liver function: an illustrated review
2023cites this paper
Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 2
2023cites this paper
Anticoagulation in Patients with Chronic Kidney Disease
2023cites this paper
Association of high-estimated glomerular filtration rate with the severity of ischemic stroke during non-vitamin K antagonist oral anticoagulants therapy: a nationwide cohort study
2023cites this paper
Direct Oral Anticoagulants: Navigating Through Clinical Challenges
2023cites this paper
Stroke Prevention in Atrial Fibrillation
2022influential citation
Association of Kidney Function With Risk of Adverse Effects of Therapies for Atrial Fibrillation
2022cites this paper
Impact of increased kidney function on clinical and biological outcomes in real-world patients treated with Direct Oral Anticoagulants
2022cites this paper
Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis
2022cites this paper
Safety of non-vitamin K antagonist oral anticoagulants: concerns in patients with atrial fibrillation and glomerular hyperfiltration?
2022cites this paper
Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation
2022cites this paper
Atrial Fibrillation and Anticoagulant Treatment in End-Stage Renal Disease Patients: Where Do We Stand?
2022cites this paper
The non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with high-normal renal function - A systematic review.
2022cites this paper
Oral Anticoagulation in Patients with Chronic Kidney Disease and Non-Valvular Atrial Fibrillation: The FAERC Study
2022cites this paper
Efficacy and Safety of Oral Anticoagulants for Atrial Fibrillation Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis
2022cites this paper
Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial
2022cites this paper
Long-term results of percutaneous left atrial appendage occlusion in patients with atrial fibrillation and chronic kidney disease
2022cites this paper
Prior direct oral anticoagulant dosage and outcomes in patients with acute ischemic stroke and non-valvular atrial fibrillation: A sub-analysis of PASTA registry study.
2022cites this paper
The use of non‐vitamin K oral anticoagulants in dialysis patients—A systematic review
2022cites this paper
Edoxaban vs. Warfarin in High-risk Patients with Atrial Fibrillation: A Comprehensive Analysis of High-Risk Subgroups.
2022cites this paper
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with advanced chronic kidney and liver diseases
2022cites this paper
A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease
2022influential citation
Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care
2022cites this paper
Edoxaban in cardiovascular disease management: Review
2021cites this paper
Lead thrombus under standard-dose edoxaban in a patient with normal to high creatinine clearance and protein S deficiency
2021cites this paper
Guía ESC 2020 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración de la European Association of Cardio-Thoracic Surgery (EACTS)
2021cites this paper
Oral Anticoagulant Agents in Patients With Atrial Fibrillation and CKD: A Systematic Review and Pairwise Network Meta-analysis.
2021cites this paper
Comparison of the Safety and Efficacy of Direct Oral Anticoagulants and Warfarin in Atrial Fibrillation or Venous Thromboembolism in Patients with Renal Impairment: Systematic Review, Meta-Analysis and Network Meta-Analysis.
2021cites this paper
Mild Renal Dysfunction and Risk of Thromboembolism and Bleeding in Patients with Atrial Fibrillation: The Chinese Atrial Fibrillation Registry Study
2021cites this paper
Oral anticoagulation in chronic kidney disease with atrial fibrillation.
2021cites this paper
Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation
2021cites this paper
Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4–5 Chronic Kidney Disease or on Dialysis
2021cites this paper
Renal Disease and Atrial Fibrillation.
2021cites this paper
Analysis of the Introduction in Clinical Practice of New Oral Anticoagulants in Local Health Agency BT: Translation of the Clinical Trial Data to a Local Health Care Area
2021cites this paper
Use of Non-vitamin K Antagonist Oral Anticoagulants for Stroke Prevention across the Stroke Spectrum: Progress and Prospects
2021cites this paper
Critical appraisal and issues regarding generalisability of comparative effectiveness studies of NOACs in atrial fibrillation and their relation to clinical trial data: a systematic review
2021cites this paper
Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis
2021cites this paper
Clinical Evidence for the Choice of the Direct Oral Anticoagulant in Patients with Atrial Fibrillation According to Creatinine Clearance
2021cites this paper
Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity.
2021cites this paper
Optimizing prognosis in atrial fibrillation: A call to action in Portugal.
2021cites this paper
AntiCOAgulAnt treAtment in PAtientS with AtriAl fibrillAtiOn And ChrOniC kidney diSeASe
2021cites this paper
Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min
2021cites this paper
Pharmacokinetics and Pharmacodynamics of DOAC
2021cites this paper
Antikoagulantna terapija u bolesnika s fibrilacijom atrija i kroničnom renalnom insuficijencijom
2021cites this paper
Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum.
2021cites this paper
Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review
2021cites this paper
Use of DOAC in Patients with Kidney Disease
2021cites this paper
Antikoagulation bei chronisch nierenkranken Menschen mit Vorhofflimmern
2021influential citation
Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis
2021cites this paper
The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation
2021cites this paper
Interdisziplinäre Aspekte der oralen Antikoagulation mit NOAKs bei Vorhofflimmern
2021cites this paper
Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation
2021cites this paper
Effect of anticoagulants on kidney function in patients with non-valvular atrial fibrillation
2021cites this paper
2021 Korean Heart Rhythm Society Guidelines: Management of Atrial Fibrillation in Specific Clinical Settings
2021cites this paper
Direct-Acting Oral Anticoagulants in Atrial Fibrillation: What's New in the Literature.
2020cites this paper
Comparative Clinical Outcomes of Edoxaban in Adults With Nonvalvular Atrial Fibrillation.
2020cites this paper
Use of NOAC in clinical practice of stroke: Expert Opinion of the Turkish Society of Cerebrovascular Diseases
2020cites this paper
Сравнительная эффективность и безопасность прямых пероральных антикоагулянтов у пациентов с неклапанной фибрилляцией предсердий и сниженной функцией почек
2020cites this paper
Concomitant diabetes with atrial fibrillation and anticoagulation management considerations
2020cites this paper
Anticoagulation for Atrial Fibrillation in Advanced Chronic Kidney Disease
2020cites this paper
Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy
2020cites this paper
Anticoagulación oral en la enfermedad renal crónica con fibrilación auricular
2020cites this paper
DARE to Prescribe: Strategy to Guide Direct Oral Anticoagulant Therapy
2020cites this paper
Should we monitor the direct oral anticoagulants?
2020cites this paper
Outcomes in VKA‐treated patients with atrial fibrillation and chronic kidney disease: Clinical trials vs ‘real‐world’
2020cites this paper
Optimizing prognosis in atrial fibrillation: A call to action in Portugal.
2020cites this paper
Arrythmias in Chronic Kidney Disease: Working Towards a Clinical Approach in Atrial Fibrillation
2020cites this paper
Efficacy and safety of left atrial appendage occlusion in atrial fibrillation patients with chronic kidney disease: a systematic review and meta-analysis.
2020cites this paper